Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Reichardt

Showing results (31-40 of 193) with videos related to

Pageof 20
Sort By:
Expert Review of Anticancer Therapy|May 16, 2012
Gastrointestinal stromal tumors: evolving role of the multidisciplinary team approach in managementPeter Reichardt, Carlo Morosi, Eva Wardelmann, et al.
Technology in Cancer Research & Treatment|April 3, 2019
Malignancy in Giant Cell Tumor of Bone: A Review of the LiteratureEmanuela Palmerini, Piero Picci, Peter Reichardt, et al.
Future Oncology (London, England)|October 10, 2006
Docetaxel in the treatment of gastric cancerPeter C Thuss-Patience, Albrecht Kretzschmar, Peter Reichardt
Seminars in Oncology|October 19, 2004
Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda)Robert Leonard, David Miles, Peter Reichardt, et al.
Future Oncology (London, England)|June 5, 2015
Trabectedin clinical cases: use according to indication in diverse clinical scenariosGiovanni Grignani, Javier Martín-Broto, Markus Schuler, et al.
European Journal of Pediatrics|May 16, 2002
Possible activation of an intramyocardial inflammatory process ( Staphylococcus aureus)after treatment with infliximab in a boy with Crohn diseasePeter Reichardt, Ingo Dähnert, Gabriele Tiller, et al.
Medizinische Klinik (Munich, Germany : 1983)|February 28, 2006
[Recent progress in the treatment of colorectal cancer]Peter C Thuss-Patience, Peter Reichardt, Hanno Riess, et al.
Plos One|July 23, 2013
Transiently reduced PI3K/Akt activity drives the development of regulatory function in antigen-stimulated Naïve T-cellsEloho Etemire, Marco Krull, Mike Hasenberg, et al.
Expert Review of Anticancer Therapy|May 1, 2020
Different approaches to advanced soft tissue sarcomas depending on treatment line, goal of therapy and histological subtypeJavier Martín-Broto, Peter Reichardt, Robin L Jones, et al.
Journal of Gastrointestinal Cancer|October 6, 2010
Response to nilotinib as a first-line treatment for metastatic gastrointestinal stromal tumorsMarcus Schlemmer, Nicole Schinwald, Christiane Bruns, et al.
Pageof 20

Showing results (31-40 of 193) with videos related to

Sort By:
Pageof 20
Expert Review of Anticancer Therapy|May 16, 2012
Gastrointestinal stromal tumors: evolving role of the multidisciplinary team approach in managementPeter Reichardt, Carlo Morosi, Eva Wardelmann, et al.
Technology in Cancer Research & Treatment|April 3, 2019
Malignancy in Giant Cell Tumor of Bone: A Review of the LiteratureEmanuela Palmerini, Piero Picci, Peter Reichardt, et al.
Future Oncology (London, England)|October 10, 2006
Docetaxel in the treatment of gastric cancerPeter C Thuss-Patience, Albrecht Kretzschmar, Peter Reichardt
Seminars in Oncology|October 19, 2004
Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda)Robert Leonard, David Miles, Peter Reichardt, et al.
Future Oncology (London, England)|June 5, 2015
Trabectedin clinical cases: use according to indication in diverse clinical scenariosGiovanni Grignani, Javier Martín-Broto, Markus Schuler, et al.
European Journal of Pediatrics|May 16, 2002
Possible activation of an intramyocardial inflammatory process ( Staphylococcus aureus)after treatment with infliximab in a boy with Crohn diseasePeter Reichardt, Ingo Dähnert, Gabriele Tiller, et al.
Medizinische Klinik (Munich, Germany : 1983)|February 28, 2006
[Recent progress in the treatment of colorectal cancer]Peter C Thuss-Patience, Peter Reichardt, Hanno Riess, et al.
Plos One|July 23, 2013
Transiently reduced PI3K/Akt activity drives the development of regulatory function in antigen-stimulated Naïve T-cellsEloho Etemire, Marco Krull, Mike Hasenberg, et al.
Expert Review of Anticancer Therapy|May 1, 2020
Different approaches to advanced soft tissue sarcomas depending on treatment line, goal of therapy and histological subtypeJavier Martín-Broto, Peter Reichardt, Robin L Jones, et al.
Journal of Gastrointestinal Cancer|October 6, 2010
Response to nilotinib as a first-line treatment for metastatic gastrointestinal stromal tumorsMarcus Schlemmer, Nicole Schinwald, Christiane Bruns, et al.
Pageof 20